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ABSTRACT 
 
Objective: To challenge retrospectively the treatment outcomes of 
vesicoureteral reflux (VUR) management according to new EAU Paediatric 
Urology Guideline Risk Grouping on VUR. 
Methods: The records of the patients who received medical and/or surgical 
treatment between 2009-2012 due to VUR were reviewed. History, 
demographic variables, diagnostic features (presence of renal scar, grade of 
reflux, laterality), clinical course, causes of failure, secondary intervention type 
and follow-up variables were analyzed. The patients were classified as low, 
moderate and high-risk groups according to EAU paediatric urology guideline. 
Treatment failure is defined as new urinary tract infection and presence of new 
renal scar during follow-up. 
Results: A total of 157 patients with 232 renal units (RU) were treated due to 
VUR. 33(71.7%) of 46RU’s were treated with sub-ureteric injection and 
18(39.1%) unsuccessful RU’s were treated with re-injection in low risk group. 
Only 2(11.1%) re-injected RU’s had postoperative UTI and/or new renal scar at 
follow-up. In moderate risk group, 54 and 7 of 61 unsuccessful RU’s were 
treated with re-injection and ureteral re-implantation, respectively. 4(7.4%) of 
54 had postoperative UTI and/or new renal scar at follow-up. In high-risk group, 
13 and 12 of 25 unsuccessful RU’s treated with re-injection and ureteral re-
implantation, respectively. 
Conclusion: We detected over treatment in low risk group. Success of the 
surgical correction was evident in moderate and high-risk group. The surgeon 
should be more pursuer in low risk and more invasive in moderate and high-risk 
group. 
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ÖZET 
 
Amaç: Vezikoüreteral reflüde (VUR) risk gruplaması konusundaki yeni EAU 
kılavuzlarına göre VUR için yaptığımız tedavilerin sonuçlarının tekrar 
değerlendirilmesi. 
Yöntem: 2009-2012 yılları arasında VUR nedeniyle medikal veya cerrahi tedavi 
görmüş hastaların kayıtları tekrar incelendi. Hikaye, demografik veriler, tanı 
esnasındaki klinik özellikler (renal skar varlığı, reflü derecesi, reflü yönü), klinik 
seyir, başarısızlık nedenleri, ikincil girişim tipi ve takipte elde edilen veriler 
değerlendirildi. EAU kılavuzlarına göre hastalar düşük, orta ve yüksek risk 
gruplarına ayrıldı. Tedavi başarısızlığı, yeni tanımlanan üriner sistem enfeksiyonu 
ve takipte yeni oluşan renal skar olarak kabul edildi. 
Bulgular: VUR nedeniyle 159 hastanın 232 renal ünitesi tedavi edilmişti. Primer 
tedavi ile elde edilen sonuçlar tablo 1'de özetlenmiştir. Düşük risk grubunda olan 
46 RÜ'nün 33(%71.7)'ü subüreterik enjeksiyon ile tedavi edilmişti. Bu hastalar 
arasında başarısız ilk tedavi nedeniyle re-enjeksiyon yapılan 18(%39.1) hasta 
mevcuttu. Re-enjeksiyon yapılıp takipte yeni renal skar tespit edilen veya üriner 
sistem enfeksiyonu geçiren sadece 2(11.1%) hasta vardı. Orta risk grubunda ilk 
tedavisi başarısız olan 61 hastanın 54'ü re-enjeksiyon, 7'si üreteral re-
implantasyon ile tedavi edildi. 54 hastanın 4(%7,4)'ünde takipte yeni renal skar 
veya üriner sistem enfeksiyonu tespit edildi. Yüksek risk grubunda ilk tedavisi 
başarısız olan 25 hastanın 13'ü re-enjeksiyon, 12'si üreteral re-implantasyon ile 
tedavi edildi. 
Sonuç: Düşük risk grubunda gereksiz tedavi uygulanmış olduğunu söyleyebiliriz. 
Orta ve yüksek risk grubu hastalarda cerrahi tedavinin başarısı daha belirgindi. 
Cerrah, düşük risk grubunda daha sık takip kararı vermeli, orta ve yüksek risk 
grubunda ise daha girişimsel davranmalıdır kanaatindeyiz. 
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INTRODUCTION 
 
Vesicoureteral reflux (VUR) is a very common urological anomaly that 
affects nearly 1% of children in the population (1). In fact, management of VUR 
is one of the most controversial issues in paediatric urology. Preventing renal 
damage is the main goal of treatment. However, new renal scars can be 
occurred due to presence of febrile urinary tract infection (UTI), high-grade 
reflux, bilateral VUR, cortical abnormalities and lower urinary tract dysfunction 
(LUTD). Current treatment options include re-implantation of the ureters, 
continuous antibiotic prophylaxis (CAP), sub-ureteric endoscopic injections by 
using different materials, or a combination of interventions. The presence of 
renal scars, renal functions, clinical course, grade and laterality of reflux, 
associated anomalies, lower urinary tract functions, age, compliance, and 
parental preference are the key factors for determining best management of 
VUR (2). The optimal management of VUR is controversial and has been 
discussed over more than thirty years several times in the literature. The 
traditional approach of initial medical treatment after diagnosis and shifting to 
interventional treatment in case of breakthrough infections and new scar 
formation needs to be challenged.  
Although medical therapy with antibiotics and surgical correction are both 
recommended to treat VUR, until now it is not clear which type of treatment is 
superior because there are contradictory studies. It is not clear that the 
interventional treatments are really necessary in patients with low grade reflux 
or is there an overtreatment issue in these patients. On the other hand, the 
question is, in the patients with high grade reflux; if the conventional therapies 
are sufficient enough to protect the kidney from reflux nephropathy. 
European Urology Association (EAU) guideline committee established a 
new risk grouping for VUR patients to provide a better decision-making process 
(1).  We thought that it would be valuable to refer the differences between our 
clinical daily practices and actual recommendations of VUR treatment. In this 
study, we endeavored to review our treatment strategies based on EAU 
Paediatric Urology Guideline of risk grouping in children with VUR.  
 
MATERIALS AND METHODS 
 
The records of the patients who received medical and/or surgical 
treatment between 2009-2012 due to VUR were reviewed. History of disease, 
demographic variables, diagnostic features (presence of renal scar, grade of 
reflux, laterality), clinical course, causes of failure, secondary intervention type 
and follow-up variables were analyzed. The patients with VUR were classified as 
low, moderate and high-risk groups according to EAU paediatric urology 
guideline (1). Treatment failure is defined as new urinary tract infection and 
presence of new renal scar during follow-up. 
 
The children were investigated with ultrasound, VCU, and DMSA 
scintigraphy as diagnostic tools and excretory urography if needed. Study 
exclusion criteria were previous urogenital surgery, malformation (duplication 
of ureter orifices), known neurological disease and stone disease. An 
experienced radiologist in paediatric urology reevaluated all radiological 
investigations. VCU was done and VUR was graded according to International 
Reflux Study in Children standards (3). The highest VUR grade was used to 
classify each case. 
For endoscopic injection, we used Dextronamer/Hyalunoric acid (Dx/HA) 
copolymer. In cases of persistent dilating VUR, the endoscopic procedure might 
be repeated for a maximum of 3 injections. Ultrasound was done at 1 month 
after each injection. VCU was repeated if new urinary tract infection and 
presence of new renal scar were occurred during follow-up or results of the 
VUR might be changed the treatment decision. The endoscopic procedure was 
performed at 2 pediatric surgical centers. Treatment was done using general 
anesthesia. Injection was performed according to standard technique (4,5). 
Dx/HA was injected submucosally in or below the ureteral orifice at the 6 
o’clock position to create a prominent bulge and raise the distal ureter and 
ureteral orifice. The children who received CAP were prescribed trimethoprim/ 
sulfamethoxazole as the first choice. DMSA scintigraphy were repeated within 1 
year period in follow-up. The re-implantation of ureters was performed by 
Cohen surgical techniques (6).  
Statistical analysis 
Statistical analyses were done in a computer based statistical program. 
Statistical differences were calculated by chi-square test and One-way ANOVA 
between risk groups and initial treatment variables. The differences between 
demographic and disease specific features with nominal values were analyzed 
with Mann-Withney U test. Statistical significance was accepted as p<0.05.   
 
RESULTS 
 
A total of 157 patients with 232 renal units (RU) were treated due to VUR. 
Mean age of the children was 6.78±5.5 years. The demographic features of the 
patients at primary treatment were shown in table 1.The distribution of the 
patient’s outcome with primary treatment was shown in table 2. 33(%71.7) of 
46RU’s were treated with sub-ureteric injection and 18(39.1%) unsuccessful 
RU’s were treated with re-injection in low risk group. Only 2(11.1%) re-injected 
RU’s had postoperative UTI and/or new renal scar at follow-up. In moderate 
risk group, 54 and 7 of 61 unsuccessful RU’s were treated with re-injection and 
ureteral re-implantation, respectively. 4(%7.4) of 54 had postoperative UTI 
and/or new renal scar at follow-up. In high-risk group, 13 and 12 of 25 
unsuccessful RU’s treated with re-injection and ureteral re-implantation, 
respectively. 
 
Table 1. Demographic features of the patients at primary treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Continued 
Antibiotic 
Prophylaxis(CAP) 
(n=16) 
Injection 
(n=88) 
Ureteral re-
implantation  
(n=12) 
CAP 
and CIC 
(n=1) 
CAP and anti-
muscarinics 
(n=24) 
Injection+anti-
muscarinics 
(n=16) 
p 
Age (median/ years) 4.5 6.5 3.5 8 6 5.5  
Gender 
Male (n(%)) 5 (31.2) 17(19.3) 7 (58.3) 0  4 (16.7) 5(31.2) 
0.058 
 Female (n(%)) 11(68.8) 71 (80.7) 5 (41.7) 1(100) 20(83.3) 11(68.8) 
Side of VUR 
Right (n(%)) 3 (18.8) 16(18.2) 5(41.7) 1(100) 9 (37.5) 4(25) 
0.221 
Left (n(%)) 3(18.8) 28(31.8) 2(16.7) 0 6(25) 7(43.8) 
Bilateral (n(%)) 10(62.5) 44(50) 5(41.7) 0 9(37.5) 5(31.2) 
Presence of 
renal scar in 
initial DMSA  
yes (n(%)) 9(56.2) 55(62.5) 11(91.7) 1 (100) 15(62.5) 13(81.2) 
<0.001 
no(n(%)) 7(43.8) 33(37.5) 1 (8.3) 0 9(37.5)) 3(18.8) 
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Table 2. The distribution of the patient’s outcome with primary treatment according to VUR risk grouping 
 
Continued 
Antibiotic 
Prophylaxis (CAP) 
Injection 
Ureteral re-
implantation 
CAP and 
CIC 
CAP and anti-
muscarinics 
Injection+ anti-
muscarinics 
p 
Low 
risk(n=46RU) 
Success(n(%)) 0 26(78.8)   0 2(100) 
<0.001 
Failure(n(%)) 9(100) 7(21.2)   2(100) 0 
Moderate 
risk(n=144RU) 
Success(n(%)) 0 62(76.5) 11(100) 0 0 10(66,7) 
<0.001 
Failure(n(%)) 8(100) 19(23.5) 0 1(100) 28(100) 5(33,3) 
High 
risk(n=42RU) 
Success(n(%)) 0 9(50) 7(100)  0 1(25) 
<0.001 
Failure(n(%)) 9(100) 9(50) 0  4(100) 3(75) 
 
 
DISCUSSION 
 
Vesicoureteral reflux is the most common urological anomaly in children 
with potentially serious consequences such as hypertension, renal scarring and 
renal failure. Reflux nephropathy is a major cause of growth impairment, 
childhood hypertension and renal insufficiency (7). The main purpose of VUR 
treatment is to protect the patient from febrile UTI, renal injury and 
accompanying morbidities. Therefore, elements such as age, gender of the 
patient, the reflux grade, history of recurrent UTI, renal dysfunction and 
associated bladder-bowel dysfunction must be evaluated and a decision must 
be made with the family. The treatment approaches are divided into 
conservative and interventional methods (8). Continued antibiotic prophylaxis, 
endoscopic injection of bulking agents and ureteral reimplantation procedures 
are the common treatment modalities of VUR. The medical management of 
VUR is based upon the observation that there is a natural evolution to 
improvement of the grade of reflux or disappearance of the VUR (9). 
In a Cochrane systematic review, 20 RCTs with 2324 children were 
reviewed on treatment options of VUR (3). The authors found that long-term 
low-dose antibiotic prophylaxis didn’t have any superiority compared to no 
treatment/placebo regarding repeat symptomatic UTI or febrile UTI at two 
years. However, antibiotic prophylaxis reduced the risk of new or progressive 
renal damage on 99mTc-DMSA (dimercaptosuccinic acid) scintigraphy (DMSA 
scan) in that period. According to risk analysis, that means 33 children would 
need long-term antibiotic prophylaxis to prevent one more child developing 
kidney damage over the course of two to three years. When they compared 
long-term antibiotic prophylaxis and surgical or endoscopic correction of VUR 
plus antibiotics, the risk of symptomatic UTI and progressive renal damage was 
not significantly different at any time point. However, combined surgical and 
antibiotic treatment caused a 57% reduction in febrile UTI by five years. It 
meant that 8 children would require combined surgical and antibiotic 
treatment to prevent one additional child developing febrile UTI by five years 
(2). In the recent prospective trial, 203 children aged 1-2 years with grade III/IV 
reflux randomized in three treatment arms including endoscopic injection, 
antibiotic prophylaxis and surveillance. The resolution rates of patients in the 
prophylaxis, endoscopic and surveillance groups are 39%, 71% and 47% after 2 
years’ follow-up, respectively.  The highest rate of febrile UTIs and scar 
formation was seen in the surveillance group at 57% and 11%, respectively. The 
recurrence rate of endoscopic treatment was found as 20%. Any patient had 
new scar formation in antibiotic prophylaxis group (4). 
These results showed us that the treatment should be tailored to different 
risk groups. According to risk classification, the children who have symptomatic 
high-grade reflux and abnormal kidney with/without LUTD need a more 
aggressive early intervention. The authors recommended open re-implantation 
for the children. However, all children who have low-grade reflux with normal 
kidneys and lower urinary tract function don’t require any treatment or only 
CAP.  
In our study, when we classified the patients into the risk groups, according 
to the EAU classification system, we saw that we treated the vast majority of 
the low risk group patients with subureteric injection. That finding shows a 
great overtreatment in this group as the EAU guideline recommends no 
treatment or only CAP in this group. There are two randomized controlled 
trials, one from Garin et al. and one from Pennesi et al., demonstrating that 
prophylactic use of antibiotics does not prevent for acute pyelonephritis and 
thus not the incidence of renal damage (10,11). Even more, Garin suggested 
that prophylactic antibiotics increased the risk of acute pyelonephritis and 
contribute to antibiotic resistance of the infecting bacteria. Immediate 
recognition and treatment of urinary tract infections is probably the most 
important factor to prevent renal scarring.  
These findings show us that we have to reconsider the accurate risk grouping of 
children to conservatively treat the patients. In our study, 11 of 18 treatment 
failures were not treated with injection or surgical interventions in low risk 
group which is compatible with EAU guideline recommendations. That may be 
due to inaccurate risk grouping of these children because of the missing data’s 
or shows that we have to reevaluate the patients if there is a real treatment 
failure condition or if it is just a follow up mistake. 
The treatment options are variable with a wide spectrum of patient 
characteristics in moderate risk group. In this group, it is favorable to start the 
treatment with CAP and endoscopic injection and ureteral reimplantation can 
be preferred as interventional treatment in case of breakthrough infections and 
persistent VUR (1). In moderate risk group, recent treatment recommendations 
according to the risk grouping system is consistent with the conventional idea 
of the management of VUR that interventional therapy should be considered if 
there is not sufficient reply to conservative treatment (12). In our study we 
analyzed that we had no successful attempt of CAP without subsequent 
intervention. Endoscopic injection and ureteral reimplantation treatment 
success rates were %75 and %100, respectively in this group. We treated 107 
(%74) of 144 renal units in moderate risk group with interventional approaches. 
It may seem like that there is an overtreatment in this group as well, but unlike 
low risk group, interventions are more critical because of high possibility of 
persistent VUR and reflux nephropathy (13). In contrast to our findings, in the 
Swedish Reflux Study, 203 children were included in this prospective 
randomized controlled multicenter study (14). They all were 1 to younger than 
2 years old during recruitment and had a grade III-IV VUR. They were 
randomized to prophylaxis, endoscopic treatment or surveillance. The main 
study end points were recurrent febrile urinary tract infection, renal status on 
dimercaptosuccinic acid scintigraphy and reflux status. There were febrile 
recurrences in 19% of girls on prophylaxis, in 23% in the endoscopic therapy 
group and in 57% of the surveillance group, so there was no difference 
between the prophylaxis and endoscopic groups. In girls the recurrence rate 
was associated with persistent reflux after 2 years. The recurrence rate in boys 
was very low and showed no differences between treatment groups. This study 
shows us that neither prophylaxis nor endoscopic treatment is of value to 
decrease recurrence after age 1 year. The very low success rate of conservative 
treatment in moderate risk group in our study can be explained with our 
tendency of advancing to an interventional treatment especially to endoscopic 
injection without following these patients for sufficient duration.  
The high success rate of open ureteral reimplantation is well documented. 
According to the Pediatric American Urological Association Guideline Panel 
Summary published in 1997 (15), the success rates of open ureteral 
reimplantation for VUR grades I to V are 99.1%, 99.0%, 98.3%, 98.5%, and 
80.7%, respectively. The success rate per patient is 95.1%, and the success rate 
per ureter is 95.9%. In addition, VUR recurrence is not observed except in those 
children with severe bladder bowel dysfunction. The success rate of endoscopic 
treatment is low compared with that of open surgery. Several authors have 
reported high success rates with injection therapy that are comparable with 
those of open ureteroneocystostomy (16–18). However, it should be 
remembered that these excellent results were attained by expert surgeons and 
that universally, there is a certain period of time required to overcome the 
steep learning curve necessary to perform these procedures. In high risk VUR 
patients it is recommended to approach more aggressively, as intervention 
should be considered early. Open ureteroneocystostomy is said to be superior 
to endoscopic treatment (1).  
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According to our data, we preferred conservative treatment in 13, injection 
in 22 and ureteral reimplantation in 7 of 42 high risk renal units. Success rates 
were %0, %45 and %100 respectively. It looks like we were not aggressive 
enough to perform sufficient initial interventional treatment. While there is an 
increased risk of reflux nephropathy in patients with high risk VUR, the 
surgeons should consider ureteral reimplantation more frequently. 
 
CONCLUSION 
 
Vesico-ureteric reflux is a frequent diagnosis in children and until now the 
optimal treatment is not always clear. To determine the most favorable 
treatment option in each individual VUR patient, it should be wise to check out 
EAU guidelines’ risk grouping system and manage the patients according to this 
system. In our study we detected over treatment in low risk group. Success of 
the surgical correction was evident in moderate and high-risk group. Further 
studies with large quantity of subjects and with long term follow up, the 
consistency between the recommendations for each risk group and treatment 
success rates should be clarified.  
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